John Sourbeer
Stock Analyst at UBS
(1.05)
# 3,534
Out of 4,711 analysts
34
Total ratings
45.45%
Success rate
-15.72%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $331.40 | +17.68% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.97 | +1.52% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $136.02 | +6.60% | 3 | Nov 5, 2024 | |
| QDEL QuidelOrtho | Upgrades: Neutral | $42 → $50 | $44.84 | +11.51% | 2 | Sep 19, 2024 | |
| OMIC Singular Genomics Systems | Maintains: Neutral | $12 → $15 | $19.55 | -23.27% | 2 | Mar 20, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $15 → $17 | $7.86 | +116.28% | 4 | Mar 15, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $337.28 | +42.31% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $2.49 | +201.20% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $57.00 | +78.95% | 3 | Mar 1, 2024 | |
| QGEN Qiagen | Maintains: Neutral | $49 → $43 | $44.67 | -3.16% | 3 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $14.04 | +256.13% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $207.51 | +30.11% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $114.23 | +12.05% | 2 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $22 | $20.56 | +7.00% | 1 | Aug 10, 2021 |
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $331.40
Upside: +17.68%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.97
Upside: +1.52%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $136.02
Upside: +6.60%
QuidelOrtho
Sep 19, 2024
Upgrades: Neutral
Price Target: $42 → $50
Current: $44.84
Upside: +11.51%
Singular Genomics Systems
Mar 20, 2024
Maintains: Neutral
Price Target: $12 → $15
Current: $19.55
Upside: -23.27%
Cryoport
Mar 15, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $7.86
Upside: +116.28%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $337.28
Upside: +42.31%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $2.49
Upside: +201.20%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $57.00
Upside: +78.95%
Qiagen
Nov 2, 2023
Maintains: Neutral
Price Target: $49 → $43
Current: $44.67
Upside: -3.16%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $14.04
Upside: +256.13%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $207.51
Upside: +30.11%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $114.23
Upside: +12.05%
Aug 10, 2021
Initiates: Neutral
Price Target: $22
Current: $20.56
Upside: +7.00%